Fermenta Biotech Limited (formerly known as DIL Limited) CIN: L99999MH1951PLC008485 Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India. Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899 Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



F.No.:908

February 11, 2025

Corporate Relations BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

Dear Sir,

Sub: Integrated Filing (Financial) - Unaudited Financial Results for the quarter and nine months ended December 31, 2024

Ref: Scrip Code 506414

Pursuant to Securities and Exchange Board of India Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, please find enclose herewith the Integrated Filing (Financial) of the Company for the quarter and nine months ended December 31, 2024 as stated below:

- A) Financial Results attached
- B) Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. **Not Applicable**
- C) Outstanding default on loans and debt securities **Not Applicable**
- D) Format for disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) **Not Applicable for quarter under consideration**.
- E) Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - Not Applicable for quarter under consideration.

Kindly take the above on record.

Thanking you,

Yours faithfully, For **Fermenta Biotech Limited**

Varadvinayak Khambete

Company Secretary & Head - Legal Membership No. A33861 Encl: As above

Factory : Village Takoli, P.O. Nagwain, Dist. Mandi - 175 121, Himachal Pradesh, India. Tel. : +91-1905-287246 / 48 / 49 Fax: +91-1905-287250 Email: info@fermentabiotech.com Website: www.fermentabiotech.com

S R B C & CO LLP

Chartered Accountants

12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) -Mumbai - 400 028, India

Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Fermenta Biotech Limited

- We have reviewed the accompanying statement of unaudited standalone financial results of Fermenta Biotech Limited (the "Company") for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP Chartered Accountants ICAI Firm registration number: 324982E/E300003

Toonam Colanda

per Poonam Todarwal Partner Membership No: 136454 UDIN: **25136454BM0JUD4153** Place: Mumbai Date: February 11, 2025



fbl

Fermenta Biotech Limited CIN:L99999MH1951PLC008485 Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majjwada, Thane (West) 400 610, Maharashtra, India. Tel:+91-22-67980888, Fax:+91-22-67980999,Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

STATEN	STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024	TER AND NINE MONTHS ENDED DECEMBER	\$ 31, 2024					
					Standalone	alone		
				Quarter Ended		Nine Months Ended	ths Ended	Year Ended
Sr.	Particulars		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
No.		ă	December 31,	September 30,	December 31,	December 31,	December 31,	March 31,
			2024	2024	2023	2024	2023	2024
-	Income							
8	a) Revenue from operations (refer note 4)		14.625.23	8.954.38	8 935 14	35 018 UE	1 2 CV 1 C	
	b) Other income		222.05	294.68	257,66	779.48	665.65	815.42
2	Total Income (a+b)		14,847.28	9,249.06	9,192.80	31,628.86	22,409.19	31,524.46
m	Expenses							
	a) Cost of materials consumed (refer note 8)		3,559.27	3,097.90	1,336.68	9,358.08	5,168.55	8,378.52
	b) Purchases of stock-in-trade		540.17	323.59	361.81	1,006.84	690.88	778.38
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress d) Employed how first success.	rk-in-progress	30.03	(535.01)	703,66	(723.80)	1,715.10	1,386.28
			1,574.04	1,422.18	1,347.45	4,450.92	4,025.18	5,393.25
	e) riliance costs f) Denreciation and amortisation exnense		409.34	369.29	516.43	1,120.96	1,363.72	1,705.21
	g) Other expenses (refer note 5)		20.200	70,200 c	49.719 49.719	CC./C/,I	1, /49.53	2,369.55
	Total expenses (a to g)		10.602.86	75.050% R 363 36	CT 10CC 17	22'CTN'01	20./05/70	21 DOE 22
4	Profit before Exceptional Items and tax (2-3)		4,244.42	885.70	1.777.98	4.645.09	358.61	77.000,1C
ъ	Exceptional Items (refer note 6))((#)	1		(00:006)	(00.006)
9	Profit/(Loss) after Exceptional Items and before tax (4-5)		4,244.42	885.70	1,777.98	4,645.09	(541.39)	(460.76)
2	Tax expense							
	a) Current tax		744.66	70.01	831	814.67	6	168.02
	b) Aujustinent on tax related to earlier years(rerer note 7)		0	00	608.27		608.27	1,245.55
	c) velerred tax charge			0	3	3		121
0	lotal tax expense (a+b+c)	080	744.66	70.01	608.27	814.67	608.27	1,413.57
х о	Prontt/(Loss) for the period/year after tax (6-7)	R.C.	3,499.76	815.69	1,169.71	3,830.42	(1,149.66)	(1,874.33)
1	(A) i) Items that will not be reclassified to Profit or Loss	TC	з	3	14	(4	10	17 28
	ii) Income tax thereon	THANE H	¢		v	b	ì	
	(B) Items that will be reclassified to Profit or Loss(net of tax)	1-11 - 00	0.82	2.12	(0.43)	3.89	1.06	6.75
		And have	0.82	2.12	(0.43)	3.89	1.06	19.03
10		~~~~	3,500.58	817.81	1,169.28	3,834.31	(1,148.60)	(1,855.30)
11	_		1,457.73	1,449.89	1,443.71	1,457.73	1,443.71	1,443.71
12			30	(9)	æ	x	8	29,978.90
13	Earnings per equity share of ₹ 5 each (not annualised)		9	39	392		筋	ę
	Earnings per equity share of ₹5 each before exceptional items S and a tems S and a tems S and S and S are shown	SIGNED FOR IDENTIFICATION	13 DF	18.0	105	CC C1	10 001	146 61
	₹ Diluted	X		2.81	4.05	13.23	(0.86)	(3.37)
	rnir	F	-					
			12.05	2.81	4.05	13.23	(3.98)	(6.49)
	D) ₹ Diluted	SRBC&COLO	12.05	2.81	4.05	13.23	(3.98)	(6.49)
	are accumpanying notes to the standarone mnancial results							
	1	INUMBAI	٦					

	form
	Ē
.,	nen
TES	Segr
2	÷

Fandalone Standalone Standalone Colspan="2">Standalone Colspan="2">Ima Montre Field Detember 31, Detember 31, S024 September 2023 Detember 31, S024 Detember 31, S023 Detember 31, S024 Detember 31, S023 Detember 31, S024 Detember 31, S023 Detember 31, S024 Detember 31, S023 S023	1. Segment Information						₹ in Lakhs
Quarter Ended Nine Months Ended Nine Months Ended Nine Months Ended Utraudited Unaudited Una				Star	ndalone		
Unaudited Z024 Z024 <thz024< th=""> Z02</thz024<>			Quarter Ended		Nine Mon	ths Ended	Year Ended
Inticulars December 31, 2024 September 30, 2024 December 31, 30, 2024 December 31, 30, 2024 December 31, 2024 December 31, 2024 <thdecember 31,<br="">2024</thdecember>		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
$ \begin{array}{c ccccc} & 2024 & 202 & 2024 & 20 \\ \hline & & & & & & & & & & & & & & & & & &$	Particulars	December 31,	September	December 31,	December 31,	December 31,	March 31,
$ \begin{array}{c} 10,258.89 \\ 10,258.89 \\ 10,258.89 \\ 8,318.23 \\ 750.62 \\ 14,447.28 \\ 750.62 \\ 14,447.28 \\ 9,249.06 \\ 9,192.80 \\ 14,847.28 \\ 9,249.06 \\ 9,192.80 \\ 14,847.28 \\ 9,249.06 \\ 9,192.80 \\ 14,70,74 \\ 25,584.36 \\ 14,447.28 \\ 3,592.14 \\ 1,709.48 \\ 1,709.88 \\ 1,015.85 \\ 1,129.98 \\ 1,709.88 \\ 1,777.98 \\ 4,645.09 \\ 4,244.42 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 4,645.09 \\ 4,244.42 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 4,645.09 \\ 6,029.15 \\ 50,084.15 \\ 50,084.15 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 887.51 \\ 59,084.15 \\ 59,084.15 \\ 50,084.15 \\ 50,084.15 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 887.51 \\ 1,990.83 \\ 2,216.97 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 897.51 \\ 59,084.15 \\ 9,280.54 \\ 8,56,073 \\ 885.70 \\ 1,777.98 \\ 4,645.09 \\ 887.51 \\ 1,900.65 \\ 1,120.96 \\ 897.51 \\ 1,900.65 \\ 1,120.96 \\ 897.51 \\ 1,900.68 \\ 1,120.96 \\ 897.51 \\ 1,900.68 \\ 1,120.96 \\ 897.51 \\ 1,900.68 \\ 1,120.96 \\ 897.51 \\ 1,900.68 \\ 1,0007.57 \\ 8991.61 \\ 1 \\ 2,800.58 \\ 1,1244.3 \\ 1,776.59 \\ 59,084.15 \\ 9,280.54 \\ 1,776.59 \\ 59,084.15 \\ 9,280.54 \\ 1,776.59 \\ 59,084.15 \\ 1,900.65 \\ 1,777.65 \\ 9,280.54 \\ 1,900.56 \\ 1,900.68$		2024	30, 2024	2023	2024	2023	2024
$ \begin{array}{c} 10,258.89 \\ \text{i} 3,337.77 \\ 265.86 \\ \text{i} 3,337.77 \\ 265.86 \\ \text{i} 4,139.30 \\ 750.62 \\ 14,847.28 \\ 9,249.06 \\ 9,192.80 \\ 31,628.86 \\ 3,395.16 \\ 1,799.98 \\ 1,799.98 \\ 1,799.98 \\ 1,728 \\ 9,003 \\ 119.60 \\ 9,192.80 \\ 1,729 \\ 9,280.54 \\ 1,254.99 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 1,777.98 \\ 4,645.09 \\ 10007.57 \\ 8,911.61 \\ 1,956.83 \\ 11,443 \\ 2,50756 \\ 3,476.22 \\ 3,645.43 \\ 1,1007.57 \\ 8,931.161 \\ 1,205.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,144.33 \\ 10,005.68 \\ 11,246.3 \\ 1,144.33 \\ 10,005.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,144.33 \\ 10,005.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,144.33 \\ 10,005.57 \\ 3,645.43 \\ 3,645.43 \\ 3,645.43 \\ 1,144.33 \\ 10,005.57 \\ 3,645.43 \\ 3,645.43 \\ 1,144.33 \\ 10,005.57 \\ 3,645.43 \\ 1,144.33 \\ 10,005.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1292.68 \\ 1,1244.42 \\ 1,2605.68 \\ 1,1202.69 \\ 1,177.98 \\ 4,645.09 \\ 1,777.98$							
$ \begin{array}{c} 10,258.89 \\ 3,337.77 \\ 265.86 \\ 7,139.30 \\ 750.62 \\ 1,693.89 \\ 3,837.77 \\ 265.86 \\ 4,139.30 \\ 7,369.43 \\ 14,847.28 \\ 9,249.06 \\ 9,192.80 \\ 31,528.86 \\ 2,224.41 \\ 3,893.26 \\ 9,003 \\ 119,60 \\ 4,353.76 \\ 1,254.99 \\ 1,015.85 \\ 1,015.85 \\ 1,015.85 \\ 1,015.85 \\ 1,015.85 \\ 1,015.85 \\ 3,664.35 \\ 1,015.85 \\ 1,015.85 \\ 3,959.14 \\ 3,893.26 \\ 4,645.09 \\ 4,645.09 \\ 4,645.09 \\ 4,645.09 \\ 4,645.09 \\ 4,645.09 \\ 4,645.09 \\ 6,029.15 \\ 1,0007.57 \\ 8,911.61 \\ 5,0084.15 \\ 8,911.61 \\ 5,007.88 \\ 5,008.415 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.09 \\ 5,0084.15 \\ 4,645.00 \\ 4,546.00 \\ 4,546.00 \\ 4,546.00 \\ 4,546.00 \\ 4,546.00 \\ 4,546.00 \\ 4,546.00 \\ 4,546.00 \\ 4,546.00 \\ 4,546.0$	Segment revenue						
$ \begin{array}{c cccccc} & 3,337.77 & 265.86 & 4,139.30 & 4,350.61 \\ & 750.62 & 664.97 & 282.76 & 1,693.89 & 31,628.86 & 2 & 282.76 & 1,693.89 & 282.76 & 1,799.98 & 1,799.98 & 1,799.98 & 1,799.98 & 1,799.98 & 1,915.64 & 3,959.16 & 3,933.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 119.60 & 3,959.14 & 3,893.26 & 90.03 & 1,777.98 & 4,645.09 & 0 & 0,024.15 & 9,875.1 & 9,875.1 & 9,875.1 & 9,875.1 & 9,875.1 & 9,875.1 & 9,875.1 & 9,875.1 & 9,875.1 & 9,875.1 & 9,875.1 & 9,280.54 & 3,8475.2 & 3,8475.6 & 5,073.85 & 11,020.55 & 3,476.52 & 3,645.43 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.683 & 11,144.32 & 16,096.68 & 11,192.683 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.683 & 11,194.43 & 16,096.68 & 11,192.683 & 11,194.43 & 16,096.68 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.683 & 11,144.33 & 16,096.68 & 11,192.633 & 11,144.33 & 16,096.68 & 11,192.633 & 11,144.33 & 16,000.64 & 11,144.33 & 16,000.64 & 11,144.33 & 16,000.64 & 11,144.33 & 16,000.64 & 11,144.31 & 16,000.64 &$	- Bulk drugs/chemicals	10,258.89	8,318.23	4,770.74	25,584.36	14.486.30	22.698.29
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	- Property (Refer Note 4)	3,837.77	265.86	4,139.30	4,350.61	6.961.33	7.374.15
	- Unallocated	750.62	664.97	282.76	1,693.89	961.56	1,452.02
899.38 1,015.85 (1,708.48) 1,799.98 ance cost 3,664.35 119.56 3,959.14 3,893.26 ance cost 4,553.76 1,254.99 2,294.41 5,766.09 (1120.96) (1369.29) (516.43) (1,120.96) (1120.96) (369.29) (516.43) (1,120.96) (1120.96) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 4,645.09 (1120.91) (1,777.98 2,216.97 (1110.91) (1,777.98 2,216.97 (1110.91) (1,580.38 2,216.97 (11,91.91) (1,580.38 2,216.97 (11,92.683 11,144.33 5,7726.59 (11,92.683 11,144.33 11,146.33 (11,92.683 11,144.33	Total Income	14,847.28	9,249.06	9,192.80	31,628.86	22,409.19	31,524.46
899.38 1,015.85 (1,708.48) 1,799.98 1,799.98 ance cost 3,959.14 3,893.26 7.2.81 72.81 ance cost 90.03 119.60 3,959.14 3,893.26 interm and tax 4,653.76 1,254.99 2,294.41 5,766.05 (409.34) (369.29) (516.43) (1,120.96) interm and tax 4,244.42 885.70 1,777.98 4,645.09 ote 6) 4,244.42 885.70 1,777.98 4,645.09 ote 6) 4,244.42 885.70 1,777.98 4,645.09 ote 6) 4,244.42 885.70 1,777.98 4,645.09 987.51 1,580.38 2,216.97 987.51 1 50,084.15 48,642.42 5,776.59 59,983.27 4 50,983.27 5,073.85 5,776.59 59,983.27 5 50,983.27 5,073.85 5,776.59 59,983.27 5 50,983.27 5,073.85 5,776.59 5,645.43 1,19,26.83 1,14,43.3 <td>Segment results</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Segment results						
3,664.35 119.54 3,959.14 3,893.26 ance cost 90.03 119.60 43.75 7.2.81 filtem and tax 4,653.76 1,254.99 2,294.41 5,766.05 i (11.120.96) (11.120.96) (1,120.96) 1(1,120.96) i (11.177.98 4,645.09 (1,120.96) 4,645.09 ote 6) 4,244.42 885.70 1,777.98 4,645.09 solo 21 1,777.98 4,645.09 987.51 1,80.38 ote 6) 4,244.2 885.70 1,777.98 4,645.09 solo 21.6 1,777.98 4,645.09 4,645.09 solo 21.6 1,777.98 4,645.09 987.51 solo 21.6 1,777.98 2,216.97 987.51 1 solo 31.61 4,854.05 5,073.85 5,716.97 987.51 solo 31.6 5,073.85 5,770.55 5,933.27 5 solo 33,61.6 5,073.85 5,770.55 5,933.27 5 solo 33,61.6 5,605.83 11,144.33	- Bulk drugs/chemicals	899.38	1,015.85	(1,708.48)	1,799.98	(4,679.70)	(4.396.46)
90.03 119.60 43.75 72.81 ance cost 4,653.76 1,254.99 2,294.41 5,766.05 (409.34) (369.29) (516.43) (1,120.96) i litem and tax 4,244.42 885.70 1,777.98 4,645.09 ote 6) 4,244.42 885.70 1,777.98 4,645.09 ote 6) 4,244.42 885.70 1,777.98 4,645.09 987.51 1,580.38 2,216.97 987.51 1 50,084.15 48,642.42 45,502.05 50,084.15 4 987.51 1,580.38 2,216.97 8,911.61 1 59,983.277 55,073.85 57,726.59 59,983.277 5 59,983.277 55,073.85 57,726.59 59,983.277 5 3,645.43 11,144.33 116,096.68 11,161 1 11,926.83 11,144.33 16,096.68 11,020.583 1	- Property	3,664.35	119.54	3,959.14	3,893.26	6,329.38	6,523.94
ance cost 4,653.76 1,254.99 2,294.41 5,766.05 (1.120.96) 1 i item and tax (409.34) (369.29) (516.43) (1,120.96) 1 i item and tax 4,244.42 885.70 1,777.98 4,645.09 4,645.09 4,645.09 1,777.98 2,216.97 987.51 1,580.38 2,216.97 987.51 1,580.38 2,216.97 9,87.51 1,580.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.97 9,87.51 1,590.38 2,216.59 5,993.27 1,590.38 1,11,44.33 1,0007.57 8,911.61 1 1	- Unallocated (Net)	90.03	119.60	43.75	72.81	72.65	16.97
(11,120,96) (11,120,96) dittem and tax 4,244,42 885.70 1,777,98 4,645.09 ote 6) 4,244,42 885.70 1,777,98 4,645.09 A 244,42 885.70 1,777,98 4,645.09 S0,084.15 48,642.42 885.70 1,777,98 4,645.09 S0,084.15 48,642.42 45,502.05 50,084.15 4 S0,084.15 1,580.38 2,216.97 987.51 1 S97.51 1,580.38 2,216.97 8,911.61 1 S9,913.27 55,073.85 57,726.59 59,983.27 5 9,280.54 8,580.76 6,029.15 9,280.54 1 3,645.43 11,44.33 11,44.33 16,096.68 11,926.83 1	Total Profit before tax and finance cost	4,653.76	1,254.99	2,294.41	5,766.05	1,722.33	2,144.45
Item and tax 4,244.42 885.70 1,777.98 4,645.09 ote 6) 4,244.42 885.70 1,777.98 4,645.09 50,084.15 48,642.42 885.70 1,777.98 4,645.09 50,084.15 48,642.42 885.70 1,777.98 4,645.09 50,084.15 48,642.42 855.70 1,777.98 4,645.09 937.51 1,580.38 2,216.97 987.51 2 8,911.61 1,580.38 2,216.97 8,911.61 10 59,983.27 55,073.85 57,726.59 59,983.27 57 59,983.27 55,073.85 57,726.59 59,983.27 57 59,280.54 8,580.76 6,029.15 9,280.54 6 9,280.54 3,456.33 11,144.33 11,096.68 11,205.83 16	- Finance costs	(409.34)	(369.29)	(516.43)	(1,120.96)	(1,363.72)	(1,705.21)
ote 6) 4,244.42 885.70 1,777.98 4,645.09 4,645.09 4,645.09 4,500,084.15 48,642.42 45,502.05 50,084.15 45 987.51 2 987.51 1,580.38 2,216.97 9,87.51 2 9,291.61 1,0007.57 8,911.51 1,0007.57 8,911.51 1,0007.57 8,911.51 1,0007.57 8,911.51 1,0007.57 8,911.51 1,0007.57 9,911.51 1,0007.57 9,911.51 1,0007.57 9,911.51 1,0007.57 9,911.51 1,0007.57 9,911.51 1,0007.57 9,911.51 1,0007.57 9,911.51 1,0007.57 9,911.51 1,0007.57 9,911.51 1,0007.50 9,011.50.568 9,0007.57 0,0	Total Profit before Exceptional item and tax	4,244.42	885.70	1,777.98	4,645.09	358.61	439.24
4,244.42 885.70 $1,777.98$ $4,645.09$ $4,645.09$ $50,084.15$ $48,642.42$ $45,502.05$ $50,084.15$ 45 $59,281.51$ $1,820.38$ $2,216.97$ 897.51 297.51 297.51 $8,911.61$ $4,851.05$ $2,216.97$ $8,911.61$ 10 $59,983.27$ $55,073.85$ $57,726.59$ $59,983.27$ 57 $59,983.27$ $55,073.85$ $57,726.59$ $59,983.27$ 57 $59,280.54$ $8,580.76$ $6,029.15$ $9,280.54$ 6 $9,280.54$ $3,850.02$ $3,476.22$ $3,645.43$ 3 $11,956.83$ $11,144.13$ $10,005.68$ $11,202.633$ $10,005.68$	- Exceptional item (refer note 6)		a:	()	98	(00.006)	(00.006)
icals 50,084.15 48,642.42 45,502.05 50,084.15 987.51 45,502.05 50,084.15 987.51 1,580.38 2,216.97 987.51 987.51 987.51 1,580.38 2,7126.59 59,983.27 55,073.85 57,726.59 59,983.27 55,073.85 57,726.59 59,983.27 55,073.85 5,073.85 57,726.59 59,983.27 1,194.33 1,1007.57 8,911.61 1,1007.57 1,007.	Total Profit / (loss) before tax	4,244.42	885.70	1,777.98	4,645.09	(541.39)	(460.76)
icals 50,084.15 48,642.42 45,502.05 50,084.15 987.51 1,580.38 2,216.97 987.51 8,911.61 987.51 55,038.15 10,007.57 8,911.61 55,938.27 55,073.85 57,726.59 59,983.27 8,911.61 59,983.27 8,911.61 59,983.27 55,073.85 55,073.85 57,726.59 59,983.27 10,007.57 10,007.57 10,007.57 10,007.57 10,007.57 10,007.57 10,007.57 10,007.57 10,007.51 10,005.81 11,007.51 10,005.81 11,007.58 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,104.33 11,005.81 11,00	Segment Assets						
987.51 1,580.38 2,216.97 987.51 987.51 8,911.61 4,851.05 10,007.57 8,911.61 9,211.61 59,983.27 55,073.85 57,726.59 59,983.27 57,726.59 59,983.27 9,280.54 8,580.76 6,029.15 9,280.54 3,456.43 11,926.83 11,144.33 16,096.68 11,926.83	gs/chen	50,084.15	48,642.42	45,502.05	50,084.15	45,502.05	45,876,77
8,911.61 4,851.05 10,007.57 8,911.61 59,983.27 55,073.85 57,726.59 59,983.27 9,280.54 8,580.76 6,029.15 9,280.54 1,1926.83 11,144.33 16,096.68 11,652.83	- Property	987.51	1,580.38	2,216.97	987.51	2,216.97	1,481.83
59,983.27 55,073.85 57,726.59 59,983.27 9,280.54 8,580.76 6,029.15 9,280.54 3,645.43 3,850.02 3,476.22 3,65.43 11,926.83 11,144.33 16,096.88 11,926.83	- Unallocated	8,911.61	4,851.05	10,007.57	8,911.61	10,007.57	9,099.24
Is 9,280.54 8,580.76 6,029.15 9,280.54 3,645.43 3,850.02 3,476.22 3,645.43 1,1926.83 11,144.33 16,096.68 11,256.83	Total Segment Assets	59,983.27	55,073.85	57,726.59	59,983.27	57,726.59	56,457.84
ls 9,280.54 8,580.76 6,029.15 9,280.54 3,645.43 3,850.02 3,476.22 3,645.43 1,192.633 11,144.33 16,095.68 11,292.683	Segment Liabilities						
3,645,43 3,850.02 3,476.22 3,645,43 11,926.83 11,144.33 16,096.68 11,926.83	- Bulk Drugs/chemicals	9,280.54	8,580.76	6,029.15	9,280.54	6,029.15	7,288.68
11,926.83 11,144.33 16,096.68 11,926.83	- Property	3,645.43	3,850.02	3,476.22	3,645.43	3,476.22	4,208.26
	- Unallocated	11,926.83	11,144.33	16,096.68	11,926.83	16,096.68	13,538.29
24,852.80 23,5/5,11 25,602.05 24,852.80	Total Segment Liabilities	24,852.80	23,575.11	25,602.05	24,852.80	25,602.05	25,035.23



SIGNED FOR IDENTIFICATION BY A B C & CO LLP MUMBAI

- The above unaudited standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 11th February, 2025. The results of the Company are available for investors at www.fermentabiotech.com and www.bseindia.com. 2
- These unaudited financial resu ts have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) m
- investment property of ₹ 3601.55 lakhs (nine months ended December 31, 2024 is ₹ 3601.65 lakhs; for the quarter ended December 31, 2023 is ₹ 3882.75 and nine months ended December 31, 2023 is ₹ 6195.12 lakhs and for During the current quarter ended December 31, 2024, the Company has sold part of its Investment in Property consisting of commercial property in Ceejay House, Worli, Mumbai and accordingly income on sale of such the year ended March 2024 ₹ 6387.82 lakhs) is recognized as income under the head revenue from operations pertaining to property segment. 4
- Subsequent to the quarter ended December 31, 2024, the Company has entered into a deed of assignment to transfer leasehold land held at Saykha, GIDC Gujrat for transfer value of ₹ 1870 Lakhs. Accordingly a provision for loss amounting to ₹480 Lakhs has been recorded under the head other expenses. S
- During the previous year ended March 31,2024, considering the prolonged subdued global demands, the Company had revisited its projected future cash flows from its subsidiary Fermenta USA LLC and has determined the value in use of its investments in the said subsidiary. Accordingly, a provision for impairment of investment of ₹ 900 lakhs was recorded as an exceptional item. 9
- During the previous year ended March 31, 2024, the Company had received intimation / final assessment order for the financial years 2016-17 to 2021-22 basis which an additional provision of tax was required on account of certain disallowances. Accordingly total MAT credit recognised of ₹ 1129.83 lakhs and Tax receivable recognised of ₹ 115.72 lakhs was written off during the previous year relating to such earlier years of which ₹ 608.27 lakhs recorded in quarter ended December 31, 2023. 2
- During the previous quarter ended September 30, 2024 cost of material consumed includes reversal of provision of a14.00 lakhs towards the semi-finished inventory used in the production of animal feed. 00

Place: Thane Date : 11th February 2025





SRBC&COLLP

Chartered Accountants

12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) Mumbai - 400 028, India

Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Fermenta Biotech Limited

- We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Fermenta Biotech Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities: Holding Company: Fermenta Biotech Limited

Subsidiaries:

- i. Fermenta Biotech (UK) Limited
- ii. Fermenta Biotech GmbH
- iii. Fermenta Biotech USA LLC
- iv. Fermenta USA LLC

Associate:

Health and Wellness India Private Limited



SRBC&COLLP

Chartered Accountants

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
 - 3 subsidiaries, whose unaudited interim financial results include total revenues of Rs 3,268.12 lakhs and Rs. 6,203.03 lakhs, total net profit after tax of Rs. 684.90 lakhs and Rs. 930.59 lakhs, total comprehensive income of Rs. 881.89 lakhs and Rs. 948.41 lakhs for the quarter ended December 31, 2024 and the period ended on that date respectively which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

- 7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:
 - 1 subsidiary, whose interim financial results and other financial information reflect total revenues of Rs. Nil and Rs. Nil lakhs, total net profit/(loss) after tax of Rs. (1.57) lakhs and Rs. 0.72 lakhs, total comprehensive income/(loss) of Rs. (1.57) lakhs and 0.72 lakhs, for the guarter ended December 31, 2024 and the period ended on that date respectively
 - 1 associate, whose interim financial results includes the Group's share of total revenues of Rs Nil and Rs. Nil, net profit of Rs. Nil and Rs. Nil, Group's share of total comprehensive income of Rs. Nil and Rs. Nil, for the quarter ended December 31, 2024 and the period ended on that date respectively and net cash outflows of Rs Nil for the period from April 01, 2024 to December 31, 2024.

The unaudited interim financial results and other unaudited financial information of the above subsidiary and associate have not been reviewed by their auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the subsidiary and associate, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.





Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

55

For S R B C & CO LLP Chartered Accountants ICAI Firm registration number: 324982E/E300003

toonam Colanoal

per Poonam Todarwal Partner Membership No.: 136454 UDIN: **25136454BMOJUE4520** Place: Mumbai Date: February 11, 2025





L

Fermenta Biotech Limited CIN:L99999MH1951PLC008485 Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India, Tel:+91-22-67980888, Fax:+91-22-67980995 Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

Interface Interface <t< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></t<>									
Particility Description Common Secret field Common	_					Consolidated			
Intermediation Intermediation Intermediation Intermediation Intermediation Intermediation Intermediation 1 Search from operation (refer rotes.) 2 Soarch 2 Soar	_		coll	+	Quarter Ended	I amonditude	Nine Months Ended	ths Ended	Year Ended
Image: Constraint of the root of the				t	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income (1) formation operation (pfor rook.) (1) formation (1) formation			7		september 3u, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024
9 (Normoun function construct (effortions i) 59000 59000 Test functions (effortions i) 23000 90000 Test functions (effortions i) 23000 90000 Test functions (effortions i) 23000 90000 Construct for functions (effortions i) 23000 90000 Construct for functions (effortions i) 20000 20000 Construct for functions (effortions i) 200000 20000 Construct for functions (effortions i) 200000 2000									
real lenser (==) (=)				15,646.96	9,502,79	9,896.70	32,962,92	23,832.34	33,566.19
Protectation 2355.3 1665.0 1 Protectation 2355.3 1665.0 1 Protectation 2365.2 1665.0 1 Protectation 2365.2 1670.0 1 Protectation 2365.2 1670.0 1 Protectation 2365.2 1670.0 1 Protectation 2365.2 1472.2 1 Protectation 2365.2 1472.2 2 Protectation 2365.2 2405.2 1 Protectation 2365.2 2405.2 2 Protectation 2365.2 235.2 2 Protectation 2365.2 235.2 2 Protectation 2365.2 235.2 2 Protectation 2365.2 235.2		Total		15,869.61	9,790.82	10,149.09	33,755.38	642.68 24,475.02	1,180.83 34,747.02
 3) Cast of metalle contantial creation of free fronts 8) 4) Contrast of disordination contantial free fronts 7) 4) Contrast of disordination contantiant fronts 7) 4) Contrast of disordination contantiant fronts 7) 4) Contrast of disordination contantiant fronts 7) 4) Contrast of disordination fronts 7) 4) Contrast of disordin disordination fronts 7) 4) Contrast of disordi		Expen							
 Change in interacting of finished goods, stock-in-trade and work-in-progress Change in interacting interacting a more constant of a mature of the mature		a) Cost of materials consumed (refer note 8) b) Purchases of stock-in-trade		2,255.37	1,866.50	1,280.27	6,841.09	4,730.73	7,700.48
 		c) Change in inventories of finished goods, stock-in-trade and work-in-progress		(195.24)	(679.79)	1,041.02	3,9/8.13 (1,092.57)	1,968.37 2.532.71	2,701.99 2.611.46
1) Oncervations and another choice 0,000		d) Employee benefits expense e) Finance costs		1,697,95	1,546.18	1,462.40	4,821.70	4,368.53	5,854.79
Table Secretional Items and tax (2-3) 1,132,24 4,336,67 1,132,24 Fort/Mixels) Electre Exceptional Items and before tax (4-5) 6,336,67 1,132,24 6,336,67 Fort/Mixels) Electre Exceptional Items and tax (2-3) 1,132,24 4,336,77 1,132,24 Fort/Mixels) Electre Exceptional Items and before tax (4-5) 0,001 1,132,24 4,336,77 1,132,24 0, Adjustment of tax 0, Adjustment of tax 0, Adjustment of tax 0,001 1,132,24 70,01 0, Adjustment of tax 0, Adjustment of tax 0, Adjustment of tax 0,001 1,112,23 1,112,23 1, Deferred tax, Adjustment of tax 0, Adjustment of tax 0,001 1,112,23 1,112,23 1, Deferred tax, Adjustment of tax 0, Adjustment of tax 0,001 1,112,23 2,001 1, Deferred tax, Adjustment of tax 0, Adjustment of tax 0,001 1,112,23 2,001 1, Deferred tax, Adjustment of tax 0,001 0,001 1,112,23 2,001 1,112,23 1, Deferred tax, Adjustment of tax 0,001 0,001 0,001 1,112,23 2,001 1, Deferred tax, Adjustment of tax 0,001 0,001 0,001		f) Depreciation and amortisation expense		608.15	614.93	638-38	1,835.36	1,826.24	1,704,60 2,471,93
Print (Alcas) before Exceptional terms and tas (2-3) (Total expenses (a to g)		4,401.59 11 335 94	3,491.47	2,768.92	11,128.95	8,018.31	11,946,43
Processional learner and before task (4-5) 1,122.24 Increational learner and before task (4-5) 1,112.24 Increational learner and before task (4-5) 1,112.24 Increational learner and before task (4-5) 1,112.24 Start (1 as prime and after task learner and before task (4-5) 1,112.24 Start (1 as prime and after task learner and learner and learner and task learner an				4,533.67	1,182.24	1,607.23	5,122.61	(335.55)	34,991,68 (244.66)
in control 4,333,01 1,122,24 in control 0 control 4,333,01 1,122,24 in control 0 fortered ax charge 7001 74,66 7001 in control 0 fortered ax charge 7001 74,66 7001 in control 10 fortered ax charge 74,66 7001 71,122,3 in control 74,65 7001 74,65 7001 in control 11,122,3 738,001 1,112,23 7001 in control 11,122,3 378,001 1,112,23 7001 in control 11,112,13 378,011 1,112,23 378,011 1,112,23 in control 11,112,13 378,011 1,112,13 378,011 1,112,13 in control 11,112,13 1,112,13 378,011 1,112,13 378,011 1,112,13 in control 11,111 1,112,13 1,112,13 1,112,13 1,112,13 1,112,13 in control 1,111,11 1,111,11 1,111,11 1,111,11 1,112,13 1,112,13 1,112,13 1,112,13 1,112,13 1,112,13 1,112	_			ж	*	ar.	12	(742.64)	(742.64)
 a) Current tax b) Guitartent tax b) Guitartent tax b) Guitartent tax b) Guitartent tax c) Ordered tax charge c) Ordered tax	_			4,533.67	1,182.24	1,607.23	5,122,61	(1,078.19)	(987.30)
Organization 0 7000000000000000000000000000000000000		a) Current tax h) Adiintement of two colored to confirment of the control of the		744.66	70.01	ia	814.67	f San N	168,02
Total as expense (e+t+c) 744.66 70.01 Pare of profit / (loss) of an associate 3789.01 1112.23 Share of profit / (loss) of an associate 3789.01 1112.23 Ret point / (loss) of an associate 3789.01 1112.23 At the parent 3601.16 1112.23 At the parent 1000000000000000000000000000000000000		u) Aujustinentu ui taxi elated to earlier years(ferer note /) c) Deferred tax charge		a a	a: a:	608.27	2 8	608.27	1,245.55
Priore (Uses) for the period after tax full before share of porti/(Uses) for the period (Uses) for the parent 378:01 1112.23 New Porti/(Uses) for the parent 378:01 1112.23 New Porti/(Uses) for the parent 378:01 1112.23 Non-controlling interests - Non-controlling interests 378:01 1112.23 Non-controlling interests - Non-controlling interests 378:01 1112.23 Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests Non-controlling interests - Non-controlling interests - Non-controlling interests - Non-controlling interests No		Total tax expense (a+b+c)		744.66	70.01	608.27	814.67	608.27	1,413,57
Net Profit/(Loss) after tax (8-9) 3/38.01 1.112.23 Attributes: - Consorting interests 3/89.1.6 1.137.96 Attributes: - Consorting interests 3/89.1.6 1.137.96 Attributes: - Consorting interests - Consorting interests - Consorting interests Attributes: - Consorting interests - Consorting interests - Consorting interests - Consorting interests A lense comprehensive income - Consorting interests - Consortinterestice - Consortinteres <th></th> <td>Profit()(LOSS) for the period after tax but before share of profit/(loss) of an associate Share of profit / (loss) of an associate</td> <th></th> <td>3,789.01</td> <td>1,112.23</td> <td>998,96</td> <td>4,307.94</td> <td>(1,686.46)</td> <td>(2,400.87)</td>		Profit()(LOSS) for the period after tax but before share of profit/(loss) of an associate Share of profit / (loss) of an associate		3,789.01	1,112.23	998,96	4,307.94	(1,686.46)	(2,400.87)
 Amenuation of the parent: Amenuation of the parent of the pa		Net Profit/(Loss) after tax (8-9)		3,789,01	1,112.23	998.96	4,307,94	(1,686.46)	(2,400.87)
-Non-controlling interests 9788 (2573) Other Comprehensitie to Profit or Loss (1) Income tax thereon 9788 (2573) It learner to defined benefit plan (1) Income tax thereon (1) Income tax thereon (1) Income tax thereon (20063) It learner to a defined benefit plan (1) Income tax thereon (1) Income tax thereon (1) Income tax thereon (20075) It learner to a defined benefit plan (1) Income tax thereon (20075) (20075) (20075) It learner to a quity instruments through other comprehensive income/(Loss) (1) Income tax through other comprehensive income/(Loss) (20075) (20075) It catel other comprehensive income/(Loss) (1) Income tax through other comprehensive income/(Loss) (20075) (20075) It catel other comprehensive income/(Loss) (1) Income (20075) (20075) (20075) It catel other comprehensive income/(Loss) (1) Income (20075) (20075) (20075) (20075) (20075) It catel other comprehensive income/(Loss) (1) Income (20075) (20075) (20075) (20075) (20075) (20075) (20075) (20075) (20075) (20075) (20075) (20075)		Attributable to: - Owners of the parent		3,691.16	1,137.96	984.85	4,247,22	(1,611,91)	(2,305.98)
 a) the state and the section of defined benefit plan b) the state and the section of the sect		- Non-controlling interests		97.85	(25.73)	14,11	60.72	(74.55)	(94.89)
() Remeasurements of defined benefit plan () Remeasurements of defined benefit plan () Income tax thereon () Income tax thereon () Next fair well be reclassified to Profit or Loss () Retrain well be reclassified to Profit or Loss () Next fair well be reclassified to Profit or Loss () Retrain well be reclassified to Profit or Loss () Next fair well be reclassified to Profit or Loss () Retrain well be reclassified to Profit or Loss () Next fair well be reclassified to Profit or Loss () Retrain well be reclassified to Profit or Loss () Next fair well be reclassified to Profit or Loss () Retrain well be reclassified to Profit or Loss () Next fair well be reclassified to Profit or Loss (10+12) () Next fair well be recompleters (10+12) () Next fair well be recent. (10+12) () Noncompleters (10+12) () Paid-up equity share of ₹5 each holore exceptional items (10+12) () Toted (10+12) () Toted (10+12)		A) Items that will not be reclassified to Profit or Loss							
 (a) Items that will be reclassified to Profit or Loss (b) Ket fair walk will be reclassified to Profit or Loss (c) Exchange different statements of foreign exchange (c) Exchange in investment in equity instruments through other comprehensive income (new (loss) (c) Exchange in investment in equity instruments through other comprehensive income (loss) (c) Exchange in investment in equity instruments through other comprehensive income (loss) (c) Exchange in investment in equity instruments through other comprehensive income (loss) (c) Exchange in investment in equity instruments through other comprehensive income/(Loss) for the period/year (10+12) (c) Exchange in investment (loss) (c) Exchange in investment (loss) (c) Exchange in investment (loss) (c) Exchange investment	_			Ŧ	19	Υ.	2	a	12.28
i) Exchange differences in translating the financials statements of foreign exchange 196,59 (205,63) ii) Net fair value change in investment in equity instruments through other comprehensive income/(Loss) 197,81 (207,52) Total other comprehensive income/(Loss) 197,81 (207,52) 904,71 Total other comprehensive income/(Loss) 386,57 904,71 386,57 904,71 Arributable co: - Owners of the parent. 386,57 904,71 386,57 904,71 Arributable co: - Owners of the parent. - Non-controlling interests. 386,57 904,71 390,44 - Non-controlling interests. - Non-controlling interests. 388,57 930,44 37,85 1,449,68 Conners of the parent. - Non-controlling interests. 388,57 930,44 37,73 1,449,68 Conners of the parent. - Non-controlling interests. 388,57 930,44 37,85 1,449,68 Conners of the parent. - Non-controlling interests. 388,57 930,44 31,45,57,73 1,449,68 Conners of the parent . - Non-controlling interests. - Non-controlling interests. 31,45,57,73 1,449,68 31,45,57,73 1,45,58 </td <th></th> <td></td> <th>100</th> <td>a a</td> <td>38 V.8</td> <td>in in</td> <td>la sa</td> <td>5 G</td> <td><u>.</u></td>			100	a a	38 V.8	in in	la sa	5 G	<u>.</u>
I) Wet fair value change in investment in equity instruments through other comprehensive income/(Loss) 2.11 I clail other comprehensive income/(Loss) 197.81 1207.32 I clail other comprehensive income/(Loss) 3.966.82 904.71 I clail other comprehensive income/(Loss) 3.966.82 904.71 Attributable to: - Owners of the parent. 3.986.87 904.71 - Owners of the parent. - Owners of the parent. 3.986.97 904.71 - Owners of the parent. - Owners of the parent. 3.986.97 904.71 - Owners of the parent. - Owners of the parent. 3.986.97 904.71 - Owners of the parent. - Owners of the parent. 3.986.97 904.71 - Owners of the parent. - Owners of the parent. 3.986.97 904.47 - Owners of the parent. - Owners of the parent. 3.986.97 904.47 Other equity share of ₹5 each fortor exceptional items BY M 1.457.73 1.449.88 I of the requity share of ₹5 each and terr exceptional items 5 8 C 1.271 3.94 I of the requity share of ₹5 each and terr exceptional items 5 8 C 1.271	_	i) Exchange differences in translating the financials statements of foreign exchange	いろうく	196,99	(209-63)	(173.21)	17.82	(114,68)	(34.45)
Total Control componentations (Loss) 197.81 1207.52) Total Componentations (Loss) for the period/year (10-12) 396.82 904.71 Attributable to: - Owners of the parent. 3,986.82 904.71 - Owners of the parent. - Owners of the parent. 3,986.82 904.71 - Owners of the parent. - Owners of the parent. 3,986.87 904.71 - Owners of the parent. - Owners of the parent. 3,986.97 904.71 - Owners of the parent. - Owners of the parent. 3,986.97 904.71 - Owners of the parent. - Owners of the parent. 3,986.97 904.71 - Owners of the parent. - Owners of the parent. 3,986.97 904.71 Paid-up equity share of ₹5 each hefore exceptional items BY M 1,457.73 1,449.89 - Owners of the requity share of ₹5 each hefore exceptional items - ₹ S ach of the requity share of ₹5 each and reaction and time exceptional items - 5 ach of the requity share of ₹5 each and reaction and the reactin and the reaction and the reaction and the	-	ii) Net fair value change in investment in equity instruments through other comprehenshive income (net)	XII	0.82	2.11	(1.49)	3.89	34	6.75
Attributable to: - Owners of the parent. - Owners of the parent of th		-07	R	197.81	(207.52)	(174.70)	21.71	(114.68)	(15.42)
- Comers of the parent.)	70,005,0	204./1	97 ⁴ 70	4,329 CO	(1,801.14)	(2,416.29)
Paid-up equity share capital (Face value ₹ 5/- per share) I,457.73 1,457.73 1,449.68 Chine requity (excluding revaluation reserve) BY I 1,457.73 1,449.68 Chine requity (excluding revaluation reserve) Earnings per equity share of ₹ 5 each hefore exceptional items BY I 1,457.73 1,449.68 Earnings per equity share of ₹ 5 each hefore exceptional items I ₹ 88.0 Earnings I 12.71 3.94 I ₹ 88.0 € CO L 1P I 12.71 3.94 I ₹ 88.0 € CO L 1P I 3.94 I ₹ 88.0 € CO L 1P I 3.94 I ₹ 88.0 € CO L 1P I 3.94 I ₹ 88.0 € CO L 1P I 3.94 I ₹ 88.0 € CO L 1P I 3.94 I ₹ 88.0 € CO L 1P I 3.94 I ₹ 88.0 € CO L 1P I I 3.94 I ₹ 88.0 € 7 000 I I		sts.	TIFICATION	3,888.97 97.85	930,44 (25-73)	810.15	4,268.93 60.77	(1,726.59) (74 55)	(2,321.40)
Earnings per quity share of ₹5 each (not annualised) Earnings per quity share of ₹5 each before exceptional items a) ₹ Basic Earnings per equity share of ₹5 each after exceptional items a) ₹ B C & CO LI.P (12.71 b) ₹ Diluted b) ₹ Diluted a) ₹ Basic b) ₹ Basic b) ₹ Basic b) ₹ Co LI.P (12.71 b) ₹ Basic b) ₹ B		Paid-up equity share capital (Face value ₹ 5/- per share)		1,457,73	1,449.89	1,443.71	1,457 73	1,443.71	1,443.71
5 R B C & CO LLP 1271 MUMBAI 1271 1271 1271		Earnings per equity share of ₹ 5 each (not annualised)				17	86	82	27,442.39
S R B C & CO LLP III		Earrings per equity share of ₹5 each before exceptional items		12 71	76 E	3.41	14 67	(101)	(E 47)
MUMBAI 1271		6 3 B C &		12.71	3.94	3.41	14.67	(10.5)	(5.42) (5.42)
Comute Consolidated financial results accompanying notes to the Consolidated financial results		MUM	BAI	12.71	3.94	3.41	14.67	(5.59)	(66.2)
		a e		12./1	3.94	3.41	14.67	(65.2)	(66°.2)

T: 26811611 110118001						₹ in Lakhs
			Consolidated	idated		
		Quarter Ended		Nine Months Ended	ths Ended	Year Ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Particulars	December 31;	September 30,	December 31,	December 31,	December 31,	March 31,
	2024	2024	2023	2024	2023	2024
Commont success						
- Bulk arugs/chemicals Droporty (Pofor Noto A)	07'T 87'TT	8,859.99	170.021	2/,/10.8b	16,550.58	25,920.84
	11.100/0	00'007	4, 137.3U	T0'000'4	55.105,0	CT.4/C//
- Unallocated	/50.64	664.97	284.32	1,693.91	963.11	1,452.03
Total Income	15,869.61	9,790.82	10,149.09	33,755.38	24,475.02	34,747.02
Segment results						
 Bulk drugs/chemicals 	1,187.17	1,312.55	(1,877.81)	2,277.06	(5,371.88)	(2,081.40)
- Property	3,664.35	119.54	3,959.14	3,893.26	6,329.38	6,523.94
- Unallocated (Net)	90.02	119.17	44.44	72.40	72.63	17.40
Total Profit before tax and finance cost	4,941.54	1,551.26	2,125.77	6,242.72	1,030.13	1,459.94
- Finance costs	(407.87)	(369.02)	(518.54)	(1,120.11)	(1,365.68)	(1,704.60)
Total Profit / (Loss) before Exceptional item and tax	4,533.67	1,182.24	1,607.23	5,122.61	(335.55)	(244.66)
 Exceptional item (refer note 6) 	28	6	00	8	(742.64)	(742.64)
Total Profit / (loss) before tax	4,533.67	1,182.24	1,607.23	5,122.61	(1,078.19)	(987.30)
Segment Assets						
- Bulk Drugs/chemicals	49,798.91	47,500.20	44,046.74	49,798.91	44,046.74	44,201.98
- Property	987.51	1,580.38	2,216.97	987.51	2,216.97	1,481.83
- Unallocated	8,911.57	4,851.02	10,015.93	8,911.57	10,015.93	9,099.27
Total Segment Assets	59,697.99	53,931.60	56,279.64	59,697.99	56,279.64	54,783.08
Segment Liabilities						
 Bulk Drugs/chemicals 	11,405.75	10,335.25	7,581.49	11,405.75	7,581.49	8,520.60
- Property	3,645.43	3,850.02	3,476.22	3,645.43	3,476.22	4,208.26
- Unallocated	11,926.43	11,143.92	16,096.50	11,926.43	16,096.50	13,537.91
Total Segment Liabilities	26,977.61	25,329.19	27,154.21	26,977.61	27,154.21	26,266,77





ED FOR IDENTIFICATION	MUC
SIGNE	ar v)

NOTES:

- The above unaudited consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 11th February, 2025. The results of the Company are available for investors at www.fermentabiotech.com and www.bseindia.com. 2
- prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') ŝ
- such investment property of ₹ 3601.65 lakhs (nine months ended December 31, 2024 is ₹ 3601.65 lakhs; for the quarter ended December 31, 2023 is ₹ 3882.75 and nine months ended December 31, 2023 is ₹ 6195.12 lakhs During the current quarter ended December 31, 2024, the parent company has sold part of its Investment in Property consisting of commercial property in Ceejay House, Worli, Mumbai and accordingly income on sale of and for the year ended March 2024 ₹ 6387.82 lakhs) is recognized as income under the head revenue from operations pertaining to property segment. 4
- Subsequent to the quarter ended December 31, 2024, the parent company has entered into a deed of assignment to transfer leasehold land held at Saykha, GIDC Gujrat for transfer value of ₹1870 Lakhs. Accordingly a provision for loss amounting to ₹ 480 Lakhs has been recorded under the head other expenses. ŝ
- During the previous year ended March 31, 2024, considering the prolonged subdued global demand, the Group had revisited its forecast of future cash flows of the business pertaining to Fermenta USA LLC. Accordingly an impairment of ₹742.64 lakhs was recorded against Goodwill created at the time of acquisition of such subsidiary, which has been disclosed as an exceptional item 9
- account of certain disallowances. Accordingly total MAT credit recognised of ₹ 1129.83 lakhs and Tax receivable recognised of ₹ 115.72 lakhs was written off during the previous year relating to such earlier years of which ₹ During the previous year ended March 31, 2024, the parent Company had received intimation / final assessment order for the financial years 2016-17 to 2021-22 basis which an additional provision of tax was required on 608.27 lakhs recorded in quarter ended December 31, 2023. ~
- During the previous quarter ended September 30, 2024 cost of material consumed includes reversal of provision of ₹ 414.00 lakhs towards the semi-finished inventory used in the production of animal feed. ∞

Date : 11th February 2025 Place: Thane



